Blog

The "Rule of 40", a decade-long standard for SaaS valuation balancing growth and profitability, is rapidly losing its predictive power in the AI era. By 2026, it will largely be superseded by the "Rule of Data" (often operationalised as the Proprietary Data Moat).The Driver: The commoditisation of foundation models has occurred faster than anticipated. By late 2024 and throughout 2025, open-source models (e.g., DeepSeek, Llama variants) effectively closed the performance gap with proprietary closed-source models for most enterprise tasks. Consequently, "model advantage" is now transient.The New Asset Class: Investors have shifted focus to the fuel rather than the engine. In 2026, valuation premiums will be assigned not to companies with the best algorithms, but to those with Proprietary, High-Fidelity and Iterate-able Data, with biological data serving as the gold standard for this new asset class.I. The Collapse of the "Rule of 40" For years, the Rule of 40 (Growth % + Profit Margin % ≥ 40) was the North Star for software investing. It assumed that code was the moat and that distribution (growth) was the primary driver of value.Why it is failing in the AI Era:Code is no longer a moat: Generative AI has lowered the barrier to entry for coding and feature development. A "feature" that once took a team of 20 engineers six months to build can now be replicated by a competitor in weeks using AI assistants and open-source libraries. Growth without defensibility is toxic: Investors in 2025 witnessed high-growth AI wrappers implode once foundation models integrated their core features natively. Growth metrics became misleading indicators of long-term value. Efficiency is table stakes: Profitability (the other half of Rule of 40) is now expected by default due to AI-driven operational efficiencies, making it less of a differentiator. II. The New Metric: The "Rule of Data" While the "Rule of 40" was a financial metric, the "Rule of Data" is a strategic defensibility metric. It evaluates the Proprietary Data Moat that prevents an AI model from being commoditised.Components of the Rule of Data:Unlike the simple arithmetic of Rule of 40, the Rule of Data is qualitative and consists of three pillars:i) Pillar ii) Description iii) Why it Valuates Higher 1. Exclusivity (The "Un-Scrapeable") Data that cannot be scraped from the open web (e.g., private patient records, internal financial logs, proprietary sensor readings). Common Crawl data is free; your internal data is a monopoly. 2. Label Fidelity (The "Truth" Layer) Raw data is noisy. Data that has been cleaned, annotated, and structured by human experts (RLHF) holds exponential value. An algorithm is only as good as its ground truth. High-fidelity labels reduce hallucination rates. 3. The Feedback Loop (The "Flywheel") Does the product generate new proprietary data as customers use it? This creates a compounding moat. The more the product is used, the better the model gets, and the harder it is to displace. &nbsp; III. The "TechBio" Case Study: Biological Data as the Ultimate Moat The user's observation about proprietary biological data being the "only defensible asset" is strongly supported by 2025 market trends. Biological data is complex, high-dimensional, and heavily regulated, making it impossible for generalist AI models (like GPT-5 or Gemini) to master without access to private repositories.Key Examples of the Data Moat in Action:Tempus AI: Their valuation is not driven by their algorithms, but by their massive library of 9M+ patient records and 4M genomic profiles. This multimodal dataset (clinical + genomic) allows them to train precision medicine models that no open-source model can replicate.​ AstraZeneca: Is pivoting from a traditional pharma model to a data-first strategy, building a "Biological Insights Knowledge Graph." They are targeting the analysis of two million genomes by 2026, creating a "data supremacy" strategy where the dataset is the primary asset, and AI is just the tool to mine it.​ Gilead Sciences: Has built a moat around decades of virology and oncology data. By centralising this into a "data mesh," they turn historical trial data into a forward-looking predictive asset. Their strategy explicitly pairs their internal data with partner algorithms, acknowledging that the algorithm is the commodity they can "rent," while the data is the asset they must "own".​ IV. Strategic Implications for 20261. The "Acqui-hire" is dead; the "Acqui-data" is born. M&amp;A strategy will shift. Tech giants will no longer buy startups for their engineering teams or novel model architectures. They will acquire companies solely to ingest their proprietary datasets. We will see traditional enterprises (banks, hospitals, logistics firms) being valued like tech companies because they sit on decades of "un-mined" proprietary data.2. Vertical AI &gt; Horizontal AI. General purpose LLMs (Horizontal AI) will race to the bottom on price. Value will accrue to Vertical AI companies that sit on top of a Proprietary Data Moat. A "Legal AI" with access to 50 years of private case files beats a generic GPT-5 every time.3. Governance as a Growth Driver. In the Rule of Data, "Data Governance" is no longer a back-office compliance task; it is a core value driver. Clean, structured, and compliant data (FAIR principles: Findable, Accessible, Interoperable, Reusable) commands a premium valuation because it is "AI-ready."Conclusion: In 2026, the question to ask is no longer "How fast are you growing?" (Rule of 40). The question is "If I gave your competitor your model architecture and unlimited compute, could they beat you?" If the answer is yes, you have no moat. If the answer is "No, because they don't have my data," you pass the Rule of Data.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title=" lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener"> lloyd@nelsonadvisors.co.uk</a>

The "Rule of 40" to be replaced by The "Rule of Data" in 2026

The first week of December 2025 was defined by two major themes: the domination of RSNA 2025 by European imaging giants and a landmark public private investment partnership to fuel the continent's life sciences sector.In Chicago, Siemens Healthineers and Philips unveiled their next-generation flagship platforms, signaling a definitive shift toward "eco-friendly" high-field MRI and AI-integrated spectral CT. On the investment front, Angelini Ventures and the European Investment Bank (EIB) signed a €150 million agreement to co-invest in European health startups, a critical move to keep deep-tech innovation within the EU.Below is a detailed analysis of the week’s key developments. 1. Innovation &amp; Product Launches (RSNA 2025 Highlights) The Radiological Society of North America (RSNA) annual meeting (Dec 1–5) is the world's premier imaging event. European heavyweights used this global stage to launch their most significant products for the 2026 fiscal year.Philips (Netherlands): The "Helium-Free" PivotPhilips continued its aggressive push into sustainable imaging with the launch of BlueSeal Horizon, the world’s first helium-free 3.0T MRI platform.​Significance: Historically, 3.0T magnets (used for high-resolution brain and musculoskeletal imaging) required thousands of liters of liquid helium. BlueSeal Horizon uses a permanently sealed magnet requiring only 7 liters, eliminating the risk of helium shortages—a major supply chain vulnerability for European hospitals in recent years. AI Integration: Philips also introduced Verida, an AI-enabled spectral CT system. Unlike previous iterations where spectral analysis was a post-processing step, Verida integrates AI directly into the imaging chain to reduce noise and improve clarity in real-time.​ Siemens Healthineers (Germany): Interventional Radiology Focus Siemens focused on expanding the clinical utility of MRI beyond diagnostics into interventional radiology (IR).Magnetom Free.XL: Launched this week, this 0.55T MRI scanner is designed specifically for the interventional suite. Its wider bore (opening) allows surgeons to perform procedures inside the scanner, and the lower magnetic field strength (0.55T) reduces heating risks for metallic interventional devices.​ AI Software: The company unveiled the Syngo.CT Coronary Cockpit, a new software module that automates the analysis of coronary CT angiography (CCTA) scans, aiming to clear the backlog of cardiac diagnostics in overburdened EU healthcare systems.​ Other European Players Agfa HealthCare (Belgium): Shifted its entire narrative to "Imaging without Barriers," showcasing a fully cloud-native Enterprise Imaging Cloud. This SaaS model allows hospitals to stream diagnostic-quality images to remote radiologists, directly addressing the radiologist shortage crisis in the UK and Germany.​ Guerbet (France): As RSNA’s "Country of Honor," France had a dedicated pavilion. Guerbet highlighted its digital health expansion, emphasizing AI tools for contrast dose management alongside its traditional pharma portfolio.​ &nbsp; 2. Investment &amp; Financial NewsAngelini Ventures &amp; EIB: A €150 Million "Deep Tech" Lifeline In a major boost for the sector, Angelini Ventures (the VC arm of Angelini Industries) and the European Investment Bank (EIB) signed a partnership to deploy €150 million into European biotech and medtech startups.​Structure: Each entity will contribute €75 million. Strategic Intent: The fund is explicitly designed to address the "Series B gap" in Europe—where promising startups often sell to US competitors due to a lack of local growth capital. First Move: The partnership’s first confirmed co-investment is in Adcytherix, a French company developing Antibody-Drug Conjugates (ADCs) for cancer therapy. (Note: Adcytherix’s Series A round closed in October, but this week’s news formalized the EIB’s strategic role in that syndicate).​ M&amp;A Activity: GE Healthineers Acquires Intelerad While GE is US-headquartered, this deal has significant ramifications for the European market. On December 2, GE Healthineers announced the acquisition of Intelerad Medical Systems for approximately $2.3 billion. Intelerad is a major provider of medical imaging software. This move consolidates the PACS/VNA market, challenging European incumbents like Agfa and Sectra by creating a more vertically integrated GE imaging ecosystem.​3. Regulatory &amp; Policy LandscapeThe "Digital Omnibus" ReactionOn December 4, MedTech Europe (the industry trade body) formally responded to the European Commission’s "Digital Omnibus" proposal.​Context: The Commission recently proposed delaying specific "high-risk" AI compliance rules for medical devices to prevent a market bottleneck. Industry Stance: MedTech Europe welcomed the delay but warned it is insufficient. They are lobbying for a "targeted postponement" of the MDR (Medical Device Regulation) re-certification deadline as well, arguing that delaying the AI Act alone solves only half of the compliance burden facing manufacturers in 2026. UK MHRA &amp; Digital Mental Health The UK’s regulator, the MHRA, issued new guidance this week on digital mental health technologies.​Impact: The guidance provides a clearer pathway for "software as a medical device" (SaMD) in mental health to gain UKCA marking. It was released alongside a £2 million funding injection to speed up the approval of these specific tools, responding to the NHS's growing waitlists for mental health services. Germany: eCTD Validation Effective December 1, 2025, Germany’s BfArM (Federal Institute for Drugs and Medical Devices) made new eCTD (electronic Common Technical Document) validation criteria mandatory. While technical, this is a critical compliance update for any medtech company whose products involve drug-device combinations submitted in Germany.&gt;&gt;&gt;The first week of December 2025 highlighted a pivotal shift in European HealthTech regulation, with the European Commission moving to unlock patient data for AI training, a long-awaited reform for the sector. In the UK, the NHS continued its digital integration with a major push into home diagnostics (HIV) and mental health regulation.On the startup front, capital is flowing into "verticalised AI" (specialised tools for specific medical niches) rather than general platforms. This was exemplified by the €3.2M seed round for La Fraise (dental AI) and the strategic partnership between Neuraxpharm and mjn-neuro to launch a seizure-prediction wearable.Below is the detailed breakdown of the week’s key trends.1. Regulation &amp; Policy: The Data &amp; AI Shift The most consequential news this week concerns the legal framework for building health AI in Europe.The "Digital Omnibus" &amp; GDPR ReformNews broke this week regarding the European Commission's "Digital Omnibus" proposal, which includes a critical update to GDPR known as the "Data Unlock."The Change: The proposal seeks to classify the training of AI models using personal data as a "legitimate interest." Impact: Currently, HealthTech startups struggle to train algorithms on patient data without explicit, granular consent from every individual. If passed, this reform would lower the legal barrier for accessing Real-World Data (RWD), potentially accelerating the development of predictive models across the EU.​ UK Mental Health "AI Airlock" In a significant move for digital therapeutics (DTx), Wellcome announced a £2 million funding injection for the UK’s regulators (MHRA and NICE) to build a dedicated "AI Airlock" for mental health apps.​What it is: A regulatory sandbox that allows companies to test digital mental health tools with the regulator before a full NHS rollout. Why it matters: Mental health apps have historically faced a "wild west" of regulation. This funding aims to create a clear, safety-first pathway for these tools to become prescribed medical devices within the NHS by 2028. &nbsp; 2. Investment &amp; Startup Activity VC activity this week signaled a strong appetite for "vertical SaaS"—software platforms dedicated to specific medical specialties.Spotlight: La Fraise (France) La Fraise ("The Strawberry") emerged from stealth with a €3.2 million Seed round backed by 20VC, Seedcamp, and Kima Ventures.​The Founders: The team includes four alumni from Doctolib, Europe’s most valuable HealthTech company. The Product: An "AI-native operating system" specifically for dental practices. It automates administrative workflows (quotes, insurance, financing) to free up clinical time. Traction: The startup claims to already have 1,200 dentists using the platform, facilitating over 30,000 treatments. This rapid adoption suggests a high demand for specialty-specific administrative AI. Ireland’s Record Year A report released on December 2 revealed that Irish health tech and life sciences companies raised a record €491.3 million in 2024 (reported retrospectively this week). This confirms Ireland's growing status as a key hub for medtech and digital health innovation, rivaling traditional centers like the UK and Germany.​ 3. Innovation &amp; Strategic PartnershipsNeuraxpharm x mjn-neuro (Spain/Germany) European CNS specialist Neuraxpharm announced a major strategic partnership with Spanish neurotech startup mjn-neuro to launch EPISERAS.​The Tech: A wearable medical device (earpiece) combined with an AI app that predicts epileptic seizures before they happen. Status: The device has received its CE Mark (Class IIa) and UKCA certification. Roadmap: While announced now, the full European commercial rollout is scheduled for the second half of 2026. This moves Neuraxpharm from a pure-play pharma company into the "digital pharma" space. NHS Digital Updates (UK) HIV Home Testing: On December 1 (World AIDS Day), the UK government unveiled a new HIV Action Plan. A core component is the integration of HIV home-testing kits directly into the NHS App, making it easier for millions of users to order discreet tests.​ Social Care Digitization: On December 4, the Department of Health announced that 80% of social care providers in England have now adopted digital social care records (DSCRs), a critical step toward a "Single Patient Record" that connects hospitals with nursing homes.​ &nbsp; 4. Event Highlights: European Digital Health Summit The European Digital Health Summit took place in Madrid (Dec 1–2), bringing together policymakers and industry leaders.​Key Themes: The discussions focused heavily on the European Health Data Space (EHDS)and the "One Health" approach. Takeaway: The consensus from the summit is that while the technical infrastructure for EHDS is being built, the governance (who accesses what data and for what purpose) remains the primary bottleneck for cross-border digital health in Europe.

This Week in European HealthTech and MedTech: 5th December 2025

Nelson Advisors has been invited to mentor and judge the MedTech Innovator 2026 programme alongside a panel of esteemed US and European industry executives.Now in its 13th year, MedTech Innovator, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care.<a data-mce-href="https://medtechinnovator.org/" href="https://medtechinnovator.org/" title="https://medtechinnovator.org/" target="_blank" rel="noopener">https://medtechinnovator.org/</a>MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Our mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide."According to Silicon Valley Bank’s CipherBio, MedTech Innovator is the largest accelerator of Life Science companies in the world. The dominant part of our portfolio is Medical Devices, in addition to our leadership position as an accelerator of diagnostics, digital health, and life science tools technologies. 93% of our portfolio are still in business or have been acquired, and 86% of our companies have raised equity financing. In Q1 2023, approximately 30% of all funds raised in the medtech sector went to a graduate of MedTech Innovator."Our corporate partners include leading manufacturers like Johnson &amp; Johnson, Dexcom, NIPRO Medical Corp., Olympus Medical Systems Group, W. L. Gore &amp; Associates, Asahi Intecc, Edwards Lifesciences, Fujikura, Jabil Healthcare, Maxim Integrated Ventures. and many others. They participate as thought leaders, application reviewers, event judges, and accelerator mentors.Hundreds of investors like RCT Ventures, Aphelion Capital, Life Science Angels, Healthtech Capital, Sofinnova Partners, Vensana, Treo, Hunniwell Lake Partners, Seroba Life Sciences participate as application reviewers, mentors, and judges.<a data-mce-href="https://medtechinnovator.org/about-us/" href="https://medtechinnovator.org/about-us/" title="https://medtechinnovator.org/about-us/" target="_blank" rel="noopener">https://medtechinnovator.org/about-us/</a>MedTech Innovator is the world’s largest accelerator of medical technology companies, with a mission to improve the lives of patients by accelerating the growth of transformative health care startups. Along with its sibling programs, BioTools Innovator and MedTech Innovator Asia Pacific, the organization provides founders with mentorship, exposure to industry leaders, and access to funding opportunities. Each year, thousands of startups compete for a place in the programs’ cohorts, gaining global visibility and connections that help bring their innovations to market faster.

Nelson Advisors invited to Mentor and Judge the MedTech Innovator 2026 Programme

Nelson Advisors Partner Lloyd Price delivered the inaugural talk to the Oxford University MedTech society sharing his journey from Consumer Internet Executive to Healthtech Entrepreneur to Non Executuve Directtor and Healthcare Technology Investment Banker.<a data-mce-href="https://www.linkedin.com/company/oxford-medtech-society/about/" href="https://www.linkedin.com/company/oxford-medtech-society/about/" title="https://www.linkedin.com/company/oxford-medtech-society/about/" target="_blank" rel="noopener">https://www.linkedin.com/company/oxford-medtech-society/about/</a> &nbsp;&nbsp; The Oxford MedTech Society is a vibrant student-led community dedicated to exploring the transformative potential of medical technology. &nbsp;&nbsp; Open to students from all disciplines, be it medicine, engineering, business, or beyond, we aim to connect aspiring innovators with leading experts and pioneers shaping the future of healthcare. Through engaging events, insightful talks from key industry leaders, and collaborative opportunities, we provide a platform for learning, networking, and co-creation in the rapidly evolving MedTech field. &nbsp;&nbsp; As a proud branch of the National MedTech Foundation, we also offer access to exciting national initiatives like hackathons, workshops, and partnerships, empowering our members to make meaningful contributions at the cutting edge of healthcare innovation. Oxford University MedTech SocietyOxford University MedTech Society is a student‑led society that emerged in the mid‑2020s to give Oxford students a dedicated hub around medical technology, distinct from older groups focused on medicine or biotechnology more broadly. It sits within the wider Oxford medtech and healthtech ecosystem, linking students with industry mentors, venture networks, and national organisations.​Founding and launchThe society was formally launched as “Oxford MedTech Society” in 2024, described publicly as a new hub for students passionate about shaping the future of medical technology.​ Early announcements highlighted a “founding committee” and positioned the group as establishing a clearer medtech presence within the Oxford student community, alongside existing societies such as the Oxford Personalised Medicine Society and Oxford University Biotech Society.​ Purpose and positioning From the outset, the society has presented itself as a “vibrant student‑led community dedicated to exploring the transformative potential of medical technology”, emphasising interdisciplinarity across medicine, engineering, computer science and entrepreneurship.​ Its remit is narrower than the general Medical Students’ Society (MedSoc) and broader than disease‑ or modality‑specific student groups, focusing on devices, diagnostics, digital health, AI in medicine, and commercialisation pathways for medtech innovations.​ Early activities and ecosystem links In its first year, Oxford MedTech Society aligned itself as an official spoke of the UK National MedTech Foundation, connecting Oxford students into a UK‑wide network of medtech interest groups and early‑career innovators.​ Founding committee members and early advisors also engaged with external bodies such as the Oxford Venture Capital Network and healthtech M&amp;A mentors, signalling an intention to bridge student interest with investors, startups and policy discussions.​ Relationship to wider Oxford medtech scene The society builds on a long Oxford tradition of medical and technological innovation but is distinct from formal academic centres like the Medical Sciences Division and history‑of‑medicine institutes, which focus on teaching and research rather than extracurricular student networking.​ It complements neighbouring societies such as the Oxford Biotech Society and Oxford Personalised Medicine Society, which already run hackathons, startup programmes and symposia, by carving out medtech as its primary lens and collaborating where topics overlapNelson Advisors'Lloyd Price is the Founder and Partner at Nelson Advisors, specialising in Healthcare Technology mergers and acquisitions, growth, and strategy, with over 25 years of experience in founding, funding, scaling, and exiting Consumer Internet and HealthTech businesses.&nbsp; &nbsp; A visionary entrepreneur, he founded Zesty, the UK’s leading patient portal acquired by Induction Healthcare PLC in 2020, and Hive Health, a pioneer in medical device cybersecurity, while also establishing The Future Health, the UK’s leading HealthTech community. Formerly a Consumer Internet executive at Kelkoo.com, Yahoo!, and Badoo/Bumble, Lloyd has driven the growth of global platforms with millions of users.&nbsp; &nbsp; He now serves as a Non-Executive Director for leading Digital Health companies and as an advisor to Oxford, Cambridge, and UCL business schools, shaping the next generation of HealthTech leaders. A founding member of the Digital Healthcare Council and a frequent speaker at industry events, Lloyd continues to advance healthcare innovation and digital transformation worldwide.'

Nelson Advisors deliver the 'Inaugural Talk' to the Oxford University MedTech Society

Nelson Advisors partner Lloyd Price co-authored the Oxford University Venture Capital Network: Insights into Digital Health Report with Ava Chan - DPhil candidate in Biology, Ellena O’Keeffe - &nbsp;MSc in Applied Cancer Science, Sili (Bobby) Qiu - DPhil candidate in Organic Chemistry, Adriana Mordente - DPhil candidate in Biology, Aneshka Moudry - MChem Chemistry. &nbsp;&nbsp; About Oxford University Venture Capital Network (OXVC)&nbsp; &nbsp;&nbsp; The Oxford University Venture Capital Network (OXVC) is a network of start-up founders, investors, and entrepreneurial Oxford students, supported by Oxford Science Enterprises and Presidio Ventures. &nbsp; For many students and founders, venture capital is a mysterious, complex, and inaccessible industry. We’re here to demystify it. &nbsp;&nbsp; VCs shape the future of the world through their investments, changing how we socialise, bank, travel, access healthcare, and beyond. However, VC is one of the least diverse industries. Women constitute only 30% of VC personnel in the UK and ethnic diversity is low. We want to change that. &nbsp;&nbsp; We take raw student talent, ambition, and vision and work directly with VC funds to provide a grounding in the theoretical and practical aspects of funding innovative ideas through to profitable outcomes. We nurture future innovators. Insights into Digital Health Report &nbsp;&nbsp; Below is an executive summary of the Oxford University Venture Capital Network: Insights into Digital Health Report: Digital Health definitionWe define Digital Health as the development and use of digital technologies making their way into products and companies for the first time to improve health outcomes. Market, Innovation &amp; Funding Landscape The largest market for digital health is in North America, whereas the fastest growing market is in the Asia-Pacific region.The biggest innovation hotspots constitute London, followed by Oxford, Cambridge and Southampton.Technology and Segment Deep Dives We provide in-depth market analysis into the digital health industry segmented into Data Collection &amp; IT, Diagnostics, Disease management and Digital therapeutics.&nbsp; Data Collection and IT As healthcare systems shift towards outcomes-based models, the demand for integrated data platforms that support personalised patient care, real-time data analytics, and efficient healthcare delivery is surging.&nbsp;New entrants in this space should focus on developing innovative, scalable health tech solutions that align with Value-Based Care principles, ensuring regulatory compliance and addressing unmet needs in patient care and data management.Market strategies should emphasise collaborating with existing healthcare players, demonstrate clear clinical and cost-efficiency outcomes and ensure seamless integration with existing healthcare systems.B2B segment to dominate the market due to increasing strategic collaborations and the building of verticals.Diagnostics (Point of Care Technology) The increasing prevalence of chronic diseases and an ageing population underscore the importance of Point of Care Technology (POCT) implementation into primary care clinics.Molecular diagnostics technology is the fastest-growing segment within POCT.POCT is a competitive market and could potentially limit product innovation and market expansion.The primary users and beneficiaries of POCT over the next five years will be doctors in hospitals and clinics, who demand a high volume of devices and consumables.Disease Management&nbsp; &nbsp;&nbsp; The CKD management market is large and growing, driven by technological innovation and increasing demand for advanced treatments. &nbsp;&nbsp; Regulatory approval in key markets like the US and UK is crucial for the adoption of new technologies.The field faces challenges such as treatment costs, access to care, and the complexity of disease management.Startups and investors active in this space have significant opportunities for innovation and growth, with the potential for lucrative exits through acquisitions or IPOs.This landscape scan provides a foundational understanding of the venture capital dynamics in the CKD management sector, highlighting the opportunities for innovation and investment in this critical area of healthcare. Digital Therapeutics (DTx) DTx has great potential, and it has a growing market. At the same time, the market is getting crowded and has a few regulatory hurdles.&nbsp;DTx can extend care to a wider group of people compared to traditional medicine.&nbsp;The main challenges include the lack of regulatory and cybersecurity infrastructure for this emerging field, and limited clinical adoption due to lack of awareness or education.Reimbursement model hinders DTx clinical translation as patients become hesitant to try out advanced technologies.&nbsp;DTx startups' go-to-market strategies need to address a broad range of stakeholders in the DTx ecosystem to gain successful market entry, and clinical adoption can be improved through digital health education.&nbsp;It is foreseeable that DTx will be integrated into emerging technologies such as smart implants and have greater emphasis on preventive care.

Nelson Advisors co author the Oxford University Venture Capital Network 'Insights into Digital Health' Report

The Nelson Advisors team is proud to support the UCL Global Business School for Health for a fourth consecutive year, mentoring and advising a diverse cohort of MBA students on healthcare technology, strategy and M&amp;A, and helping develop the next generation of global health leaders.As part of UCL GBSH’s Health Executives in Residence and mentoring programmes, we share real-world HealthTech, Digital Health and Healthcare AI insights with students exploring careers at the intersection of business and healthHighlights this year have included:1. Harvard Global Health Institute - writing letters of recommedation and support for applications to the Women’s Leadership in Global Health Fellowship at the Harvard Global Health Institute.2. &nbsp;AI-powered credit assessments, enabling "Buy Now, Pay Later" (BNPL) options for healthcare - supporting the commercial discussions, go to market strategy workshops and value proposition canvas design for an innovative emereging market project.3. Strategy project for BUPA - Revenue Models and Business Sustainability for Integrated Digital and Physical Health Models.The UCL Global Business School for Health is the world's first business school dedicated to health. We unravel health challenges from a business perspective.<a data-mce-href="https://www.ucl.ac.uk/population-health-sciences/global-business-school-health" href="https://www.ucl.ac.uk/population-health-sciences/global-business-school-health" title="https://www.ucl.ac.uk/population-health-sciences/global-business-school-health" target="_blank" rel="noopener">https://www.ucl.ac.uk/population-health-sciences/global-business-school-health</a>UCL’s Global Business School for Health is widely regarded as one of the leading health-focused business schools globally because it combines a top-10 world university brand with a unique, health-only business school model and highly applied, leadership-focused programmes.​World-class university platformUCL is consistently ranked in the global top 10 by QS and in the global top 10 by U.S. News, placing it among the very best universities worldwide and third in Europe.​ The school sits within UCL’s Faculty of Population Health Sciences, which itself ranks among the world’s top institutions for public health and population health research and education.​ First business school for health UCL GBSH is described as the world’s first business school dedicated entirely to health, created specifically to respond to the need for better healthcare management, innovation and leadership after the pandemic.​This singular focus allows it to “unravel health challenges from a business perspective”, integrating management, life sciences, digital health, and policy in a way that traditional business schools typically do not.​ Innovative health-focused programmes The portfolio spans specialised programmes such as the MBA Health, MSc Digital Health and Entrepreneurship, MSc Biotech and Pharmaceutical Management, and Global Healthcare Management, all designed to train leaders who can transform health systems.​ Curricula blend core business disciplines with healthcare-specific application, using real-world case studies, wrap‑up weeks with sector experts, and consultancy projects with live health-sector clients to ensure graduates can drive practical change.​ Global impact and diversity The school attracts an international student body and faculty, reflecting UCL’s strength as a globally connected research and education hub with one of the strongest international research networks worldwide.​ Programmes are explicitly framed around tackling global health challenges—such as health inequalities, ageing populations, and system inefficiencies—so graduates are prepared for impact in health systems around the world, not just the UK.​ Location and ecosystem advantages Based in London, including at the UCL East campus on the Queen Elizabeth Olympic Park, the school benefits from proximity to the NHS, life sciences clusters, digital health startups, and global health organisations.​ This ecosystem supports strong industry engagement, executive education, and employer links, enhancing career outcomes and reinforcing its position as one of the best places globally to study the business of health.

Nelson Advisors

Blog

The "Rule of 40" to be replaced by The "Rule of Data" in ...

This Week in European HealthTech and MedTech: 5th Decembe...

Nelson Advisors invited to Mentor and Judge the MedTech I...

Nelson Advisors deliver the 'Inaugural Talk' to the Oxfor...

Nelson Advisors co author the Oxford University Venture C...

Nelson Advisors mentor UCL Global Business School for Hea...